For US Healthcare Professionals
Select a category or scroll to learn more.
4B study: BYETTA BID vs insulin lispro TID
4B : Basal Insulin Glargine, Exenatide BID, and Metformin Therapy or Basal Insulin Glargine, Bolus Insulin Lispro, and Metformin Therapy
Objective: Compare the efficacy and safety of BYETTA (extenatide) injection, a shortacting GLP-1 receptor agonist, or bolus insulin lispro in patients inadequately controlled on a regimen of titrated insulin glargine plus metformin.
In appropriate adult patients with type 2 diabetes uncontrolled on insulin glargine and metformin in addition to diet and exercise
BYETTA 5 mcg BID for 1 month, followed by BYETTA 10 mcg BID for the remainder of the 30-week study.
BYETTA is not indicated for weight loss.
*Weight reduction was a secondary end point
In a head-to-head study vs mealtime insulin, BYETTA demonstrated:
BYETTA is not indicated for weight loss.
*Weight reduction was a secondary end point